Boston Pharmaceuticals Inc.

In the highly competitive race to follow Madrigal to market in metabolic dysfunction-associated steatohepatitis (MASH), perhaps the two most closely watched drug classes are the GLP-1 agonists, which

When Akero Therapeutics failed to meet the 36-week primary endpoint in its Phase IIb SYMMETRY study of efruxifermin in metabolic dysfunction-associated steatohepatitis (MASH) in October 2023, the comp

In the non-alcoholic steatohepatitis (NASH) space, Novo Nordisk was the star of the 2024 American Association for the Study of Liver Disease meeting with additional data from its Phase III study of se

A cluster of recent breakthrough therapy designation awards in liver disease highlight advances in the field ahead of the US Food and Drug Administration’s difficult, and now delayed, decision on the